PMID- 35282037 OWN - NLM STAT- PubMed-not-MEDLINE LR - 20220315 IS - 2305-5839 (Print) IS - 2305-5847 (Electronic) IS - 2305-5839 (Linking) VI - 10 IP - 2 DP - 2022 Jan TI - A single-arm, prospective study of apatinib mesylate plus pemetrexed in patients of advanced non-squamous non-small cell lung cancer after failure of previous chemotherapy. PG - 101 LID - 10.21037/atm-22-79 [doi] LID - 101 AB - BACKGROUND: The outcomes of advanced non-small cell lung cancer (NSCLC) patients after first- or second-line therapy are still discouraging due to a lack of effective treatment strategies. As a novel oral anti-angiogenesis drug, apatinib, approved by the National Medical Products Administration of China only for advanced gastric cancer, has been increasingly used in off-label treatment across various cancer types in recent years, especially advanced NSCLC. It has shown strong anti-tumor efficacy and acceptable safety. METHODS: This prospective study (NCT02974933) was conducted in patients with advanced NSCLC, who had suffered disease progression from the first- or second-line treatment, in Hubei Cancer Hospital. Eligible patients were enrolled and administrated with apatinib mesylate (500 mg qd) in combination with pemetrexed (500 mg/m(2), every 4 weeks). The primary endpoint was progression-free survival (PFS). RESULTS: From September 2016 to September 2019, a total of 21 advanced NSCLC patients were enrolled in Hubei Cancer Hospital. As of January 2021, treatment was discontinued in all patients, with 1 still in follow-up. There were 7/21 (33.3%) patients who achieved objective response. The median PFS and median overall survival (OS) were 7.0 months (95% CI: 6.15-7.85 months) and 13.0 months (95% CI: 7.39-18.6 months), respectively. Toxicities were tolerable or could be clinically managed. The most common grade 3-4 adverse events (AEs) were hypertension (14.3%, 3/21), hand-foot syndrome (4.7%, 1/21), and proteinuria (4.7%, 1/21). Hematological toxicities were moderate, with rare occurrences of grade 3/4 toxicities. During the period of treatment, there was no occurrence of treatment-related death. CONCLUSIONS: Apatinib plus pemetrexed demonstrated promising efficacy and a high level of safety profile in previously heavily-treated NSCLC patients. More definitive studies on the combination of apatinib and pemetrexed are warranted. CI - 2022 Annals of Translational Medicine. All rights reserved. FAU - Dong, Shuang AU - Dong S AD - Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Ou, Wuling AU - Ou W AD - Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Zhong, Yi AU - Zhong Y AD - Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Zhu, Xianmin AU - Zhu X AD - Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Cai, Qian AU - Cai Q AD - Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Zhang, Jing AU - Zhang J AD - Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Ran, Fengming AU - Ran F AD - Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Qian, Yu AU - Qian Y AD - Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Wang, Jun AU - Wang J AD - Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. FAU - Hu, Sheng AU - Hu S AD - Department of Medical Oncology, Hubei Cancer Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China. LA - eng PT - Journal Article PL - China TA - Ann Transl Med JT - Annals of translational medicine JID - 101617978 PMC - PMC8848392 OTO - NOTNLM OT - Non-small cell lung cancer (NSCLC) OT - apatinib OT - efficacy OT - pemetrexed OT - safety COIS- Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at https://atm.amegroups.com/article/view/10.21037/atm-22-79/coif). The authors have no conflicts of interest to declare. EDAT- 2022/03/15 06:00 MHDA- 2022/03/15 06:01 PMCR- 2022/01/01 CRDT- 2022/03/14 05:30 PHST- 2021/12/22 00:00 [received] PHST- 2022/01/18 00:00 [accepted] PHST- 2022/03/14 05:30 [entrez] PHST- 2022/03/15 06:00 [pubmed] PHST- 2022/03/15 06:01 [medline] PHST- 2022/01/01 00:00 [pmc-release] AID - atm-10-02-101 [pii] AID - 10.21037/atm-22-79 [doi] PST - ppublish SO - Ann Transl Med. 2022 Jan;10(2):101. doi: 10.21037/atm-22-79.